Literature DB >> 8453308

Interleukin-3 immunoassay in systemic lupus erythematosus patients: preliminary data.

P Fishman1, M Kamashta, M Ehrenfeld, J Vianna, G R Hughes, D Sredni, R Zigelman, G Sabo, Y Shoenfeld.   

Abstract

Systemic lupus erythematosus (SLE) may be associated with thrombocytopenia on one hand and lymphoma on the other. Interleukin-3 (IL-3) may contribute to both conditions. IL-3 is a pleotrophic growth factor affecting the proliferation and differentiation of stem cells to committed progenitors of several hematopoietic lineages including megakaryocytes and lymphocytes. The serum level of IL-3 determined by ELISA was found to be higher in a cohort of 16 patients with SLE in comparison to health controls. The IL-3 levels were highest in 2 patients with SLE and lymphoma. Interestingly, low serum levels were detected in SLE patients with thrombocytopenia. Our preliminary results may point to the role of IL-3 in the hematopoietic changes observed in SLE.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8453308     DOI： 10.1159/000236414

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN： 1018-2438            Impact factor:   2.749


  6 in total

1.  IL-3 contributes to development of lupus nephritis in MRL/lpr mice.

Authors:  Kerstin Renner; Fabian Johannes Hermann; Kathrin Schmidbauer; Yvonne Talke; Manuel Rodriguez Gomez; Gabriela Schiechl; Jens Schlossmann; Hilke Brühl; Hans-Joachim Anders; Matthias Mack
Journal:  Kidney Int       Date:  2015-07-01       Impact factor: 10.612

2.  A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus.

Authors:  Shereen Oon; Huy Huynh; Tsin Yee Tai; Milica Ng; Katherine Monaghan; Mark Biondo; Gino Vairo; Eugene Maraskovsky; Andrew D Nash; Ian P Wicks; Nicholas J Wilson
Journal:  JCI Insight       Date:  2016-05-05

3.  The regulation and pharmacological modulation of immune complex induced type III IFN production by plasmacytoid dendritic cells.

Authors:  Karin Hjorton; Niklas Hagberg; Pascal Pucholt; Maija-Leena Eloranta; Lars Rönnblom
Journal:  Arthritis Res Ther       Date:  2020-06-05       Impact factor: 5.156

4.  Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report.

Authors:  Oskar Schnappauf; Liane Heale; Dilan Dissanayake; Wanxia L Tsai; Massimo Gadina; Thomas L Leto; Daniel L Kastner; Harry L Malech; Douglas B Kuhns; Ivona Aksentijevich; Ronald M Laxer
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-23       Impact factor: 3.054

Review 5.  Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.

Authors:  Timothy A Gottschalk; Evelyn Tsantikos; Margaret L Hibbs
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

6.  A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus.

Authors:  Shereen Oon; Katherine Monaghan; Milica Ng; Alberta Hoi; Eric Morand; Gino Vairo; Eugene Maraskovsky; Andrew D Nash; Ian P Wicks; Nicholas J Wilson
Journal:  Clin Transl Immunology       Date:  2019-12-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.